23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › 10x Genomics, Inc. › 2025-2026

10x Genomics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and 10x Genomics, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 318Asset managers, any item
  • 1,804Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 5 items on 10x Genomics, Inc.’s Form 8-K, filed June 8, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (13.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore 10x Genomics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by 10x Genomics, Inc.

These tallies are 10x Genomics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

10x Genomics, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Serge Saxonov 164,137,38115,559,860557,329 --18,560,948 91%Passed (calculated)—
Elect Director: Benjamin J. Hindson 162,942,76616,761,532550,270 --18,560,950 91%Passed (calculated)—
Elect Director: John R. Stuelpnagel 155,628,36524,072,179554,023 --18,560,951 87%Passed (calculated)—
2. Ratification of Independent Registered Public Accounting Firm 197,719,939458,231637,346 ---- 99.8%Approved—
3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers 176,677,5402,828,730748,296 --18,560,952 98%Approved—

Source: 10x Genomics, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.

How asset managers voted at the 10x Genomics, Inc. 2025-2026 meeting

318 asset managers disclosed a vote on at least one 10x Genomics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Benjamin J. Hindson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 162,942,766AGAINST: 16,761,532
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Benjamin J. Hindson

10x Genomics, Inc.’s own tally for this item (“Elect Director: Benjamin J. Hindson”): 162,942,766 for, 16,761,532 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 49,127,161 for, 3,211,324 against, 10,077 abstained.

FOR
FOR: 49,127,161AGAINST: 3,211,324ABSTAIN: 10,077
Largest asset managers voting on “Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expir” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,122,04210,367 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price31,337661,961 00Against
Dimensional0484,869 00Against
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable234,06485,300 00Mixed
Nationwide33,983259,317 00Mixed
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust0250,930 00Against
Principal Exchange-Traded Funds0224,706 00Against
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For
Lincoln Financial100,67742,185 00Mixed

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: John R. Stuelpnagel

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 155,628,365AGAINST: 24,072,179
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: John R. Stuelpnagel

10x Genomics, Inc.’s own tally for this item (“Elect Director: John R. Stuelpnagel”): 155,628,365 for, 24,072,179 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 45,696,450 for, 6,642,035 against, 10,077 abstained.

FOR
FOR: 45,696,450AGAINST: 6,642,035ABSTAIN: 10,077
Largest asset managers voting on “Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expir” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity13,360,2512,489,907 00Mixed
Vanguard12,115,92616,483 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price31,337661,961 00Against
Dimensional0484,869 00Against
TIAA0403,502 00Against
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable189,160130,204 00Mixed
Nationwide33,983259,317 00Mixed
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust0250,930 00Against
Principal Exchange-Traded Funds0224,706 00Against
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen0176,714 00Against
ARK Venture Fund146,8690 00For
Lincoln Financial26,177116,685 00Mixed

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Elect Director: Serge Saxonov

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 164,137,381AGAINST: 15,559,860
Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Serge Saxonov

10x Genomics, Inc.’s own tally for this item (“Elect Director: Serge Saxonov”): 164,137,381 for, 15,559,860 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 49,924,039 for, 2,474,446 against, 10,077 abstained.

FOR
FOR: 49,924,039AGAINST: 2,474,446ABSTAIN: 10,077
Largest asset managers voting on “Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expir” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,122,04510,364 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price693,2980 00For
Dimensional0484,869 00Against
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable234,06485,300 00Mixed
Nationwide33,983259,317 00Mixed
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust0250,930 00Against
Principal Exchange-Traded Funds0224,706 00Against
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For
Lincoln Financial100,67742,185 00Mixed

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 14 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 176,677,540AGAINST: 2,828,730

Prior year: 83.6% for (June 3, 2025 meeting) ▲ 14.8 pts

Details: description as filed, official tally, votes by 318 asset managers

Description as filed by funds: A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and

10x Genomics, Inc.’s own tally for this item (“3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 176,677,540 for, 2,828,730 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 81 asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,132,4053 30For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group01,452,300 00Against
Charles Schwab1,113,6940 00For
T. Rowe Price693,2980 00For
Dimensional484,8690 00For
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable319,3640 00For
Nationwide293,3000 00For
American Century0291,528 00Against
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust250,9300 00For
Principal Exchange-Traded Funds224,7060 00For
HUSSMAN INVESTMENT TRUST00 200,0000Abstain
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For

Fund voting reports, all 81 managers: 50,515,091 for, 1,815,393 against, 210,078 abstained, 1 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 263 asset managers voting on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity18,403,2710 00For
Amova Asset Management Co., Ltd.5,090,3950 00For
BlackRock3,233,3550 00For
GEODE CAPITAL MANAGEMENT, LLC2,904,4160 00For
State Street2,232,1680 00For
T. Rowe Price1,541,2270 00For
Capital Group01,452,300 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC1,148,5790 00For
Charles Schwab1,115,7630 00For
Blue Water Life Science Advisors, LP1,089,9750 00For
Vanguard987,3680 00For
AQR985,1070 00For
Northern Trust811,9110 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC807,9280 00For
ARK Investment Management LLC743,5960 00For
Goldman Sachs684,9010 00For
Nuveen625,8670 00For
Federated Hermes593,2630 00For
Freshford Capital Management, LLC587,1490 00For
STATE OF MICHIGAN RETIREMENT SYSTEM572,9250 00For
Janus Henderson512,0280 00For
Connor, Clark & Lunn Investment Management Ltd.505,9020 00For
Sands Capital Alternatives, LLC481,7700 00For
BOSTON MANAGEMENT & RESEARCH467,0790 00For
Russell Investments440,8430 00For

Institutional-manager reports, all 263 managers: 52,853,812 for, 2,338,954 against, 530,146 abstained, 735 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 197,719,939AGAINST: 458,231

Prior year: 99.9% for (June 3, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

10x Genomics, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 197,719,939 for, 458,231 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 52,338,484 for, 10,077 abstained.

FOR
FOR: 52,338,484ABSTAIN: 10,077
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at 10x Genomics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity15,850,1580 00For
Vanguard12,132,4080 20For
ARK ETF Trust9,942,3480 00For
BlackRock4,178,5910 00For
Capital Group1,452,3000 00For
Charles Schwab1,113,6940 00For
T. Rowe Price693,2980 00For
Dimensional484,8690 00For
TIAA403,5020 00For
Pacific Life382,1180 00For
JPMorgan375,2910 00For
Russell Investments367,0390 00For
Goldman Sachs361,9470 00For
Simplify Exchange Traded Funds348,3570 00For
Equitable319,3640 00For
Nationwide293,3000 00For
American Century291,5280 00For
Columbia Threadneedle256,0510 00For
Janus Detroit Street Trust250,9300 00For
Principal Exchange-Traded Funds224,7060 00For
AMERICAN BEACON FUNDS183,1650 00For
QUANTITATIVE MASTER SERIES LLC179,2520 00For
Nuveen176,7140 00For
ARK Venture Fund146,8690 00For
Lincoln Financial142,8620 00For

Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).

Largest 10x Genomics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 127,691,329 shares outstanding at the time of that meeting.

Fund voting reports: top 10x Genomics, Inc. shareholders by shares voted on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 12.41%
2Vanguard 9.50%
3ARK ETF Trust 7.79%
4BlackRock 3.27%
5Capital Group 1.14%
6Charles Schwab 0.87%
7T. Rowe Price 0.54%
8Dimensional 0.38%
9TIAA 0.32%
10Pacific Life 0.30%
Institutional-manager reports: top 10x Genomics, Inc. shareholders by shares voted on “A vote to approve, on a non-binding, advisory basis, the compensation of our named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.41%
2Amova Asset Management Co., Ltd. 3.99%
3BlackRock 2.53%
4GEODE CAPITAL MANAGEMENT, LLC 2.27%
5State Street 1.75%
6T. Rowe Price 1.21%
7Capital Group 1.14%
8JACOBS LEVY EQUITY MANAGEMENT, INC 0.90%
9Charles Schwab 0.87%
10Blue Water Life Science Advisors, LP 0.85%

Reported 10x Genomics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

10x Genomics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)17,740,972 13.89%Form 13F, quarter ended March 31, 2026
T. Rowe Price Associates, Inc.14,044,020 11.00%Schedule 13G, filed September 8, 2026
Vanguard Group13,017,914 10.19%Form 13F, quarter ended March 31, 2026
BlackRock10,079,913 7.89%Form 13F, quarter ended March 31, 2026
ARK Investment Management LLC10,003,058 7.83%Schedule 13G, filed August 14, 2026
Vanguard Portfolio Management6,981,683 5.47%Schedule 13G, filed April 28, 2026
Goldman Sachs4,109,100 3.22%Form 13F, quarter ended March 31, 2026
Morgan Stanley3,196,893 2.50%Form 13F, quarter ended March 31, 2026
State Street2,588,795 2.03%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors2,042,950 1.60%Form 13F, quarter ended March 31, 2026

Percentages above are of 127,691,329 shares outstanding, as reported by 10x Genomics, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At 10x Genomics, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 318 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,804 separate fund positions. On the most widely held item on that ballot — A vote to approve, on a non-binding, advisory basis, the compensation of our named executive… — 10x Genomics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 10x Genomics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10x Genomics, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

10x Genomics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “10x Genomics (TXG) 2026 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/10x-genomics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.